Afuco™ Anti-RSV F ADCC Therapeutic Antibody (Motavizumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to RSV glycoprotein F. Motavizumab is a humanized monoclonal antibody for the prevention of respiratory syncytial virus infection in high-risk infants.
Supplier Creative Biolabs
Product # AFC-TAB-709
Pricing Inquiry
Host Human
Target RSV F
Species Reactivity RSV
Type ADCC enhanced antibody
Applications IF, IP, Neut, FuncS, ELISA, FC
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback